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Bone Marrow Cells Released After Acute MI
Wojakowski and colleagues have been studying a line of bone marrow cells thatdisplay not only cardiac and endothelial cell markers, but also several develop-
mentalmarkers characteristic for pluripotent stem cells. Based on their small size, these
cells have been named very small embryonic-like stem cells (VSELs). The number of
circulating VSELs in patients with a recent myocardial infarction (MI) was studied.
Within 12 h of MI symptoms, the number of circulating VSELs increased compared
with healthy controls, and remained elevated through 5 days. The mobilization of
VSELs was significantly reduced in patients age 50 years, those with diabetes, and
those with large infarctions. Acute MI induces mobilization of VSELs, but several
high-risk categories of patients have blunted mobilization. See pages 1 and 10.
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Heart Failure
Declining Post-MI Mortality in Elderly,
But Increasing CHF Diagnoses Among Survivors
Ezekowitz and colleagues studied a cohort of over 7,000 elderly (65 years of age)patients who suffered a first myocardial infarction (MI) between 1994 and 2000
and had no prior history of heart failure (HF). During the index MI hospitalization,
37% of MI patients were diagnosed with new HF and 13% died. Among hospital
survivors who did not haveHF during their index hospitalization, 64%developedHF
in the first year. The 5-year mortality rate was 39% for those withHFwith their index
MI compared to 27% among those without HF. Over the study period, the 5-year
mortality rate afterMI fell by 28%,whereas the 5-year rate ofHF increased by 25%. In
this large cohort of elderly patients, three-quarters of patients developed HF in the 5
years after their first MI; this proportion increased despite the fact that, or possibly
because, peri-MI mortality rates declined. See pages 13 and 21. See figure.
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Heart Rhythm Disorders
Ramipril May Prevent Recurrences of Lone AF
Several studies have shown that angiotensin-converting enzyme (ACE) inhibitorsare effective in preventing atrial fibrillation (AF) relapses in patients with arterial
hypertensionor other formsof heart disease. Belluzi and colleagues performed a clinical
trial to investigate whether the ACE inhibitor ramipril prevents AF relapses in patients
with lone AF. Sixty-two patients with a first episode of lone AF were enrolled in the
study after excluding the presence of cardiac or extracardiac conditions known to
increase the risk of AF, including hypertension and echocardiographic abnormalities.
After cardioversion, patients were randomized to either ramipril or placebo. After 3
years, AF relapses were observed in 3 patients treated with ramipril and in 10 patients
allocated to placebo. Patients assigned to ramipril hadminor decreases in left atrial size
and blood pressure, while those assigned to placebo had slight increases in both. See
pages 24 and 30. See figure.
Cardiac Imaging
Ultrasound Contrast Appears to Be Safe for Echocardiography
Dolan and colleagues retrospectively analyzed over 40,000 patients who hadrecevied aUCA to determine their safety and value for patients with suboptimal
images or inwhomechocardiographicmyocardial perfusionwas assessed.Nodeaths or
myocardial infarctions (MIs) were observed within 30 min. There were no significant
differences in death rates orMIs at 1 or 30 days compared with amatched cohort who
underwent echocardiographywithoutUCA.Despite recent warnings regardingUCA,
these findings indicate that it is a safe and a useful diagnostic tool. See page 32.
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Valvular Heart Disease
Undersized AVR Increases Late Mortality
Mohty and colleagues have previously demonstrated that aortic valve replacement(AVR)with a lowbodymass indexedvalve effective orifice area (EOA) increases
30-day mortality, particularly in patients with reduced left ventricular function. For
this article, the outcomes of patients who survived at least 30 days were reviewed. No
prosthesis-patientmismatch (PPM)was defined as thosewith anEOA0.85 cm2/m2,
as moderate if0.65 and0.85 cm2/m2, and severe if0.65 cm2/m2. Severe PPM
was associated with increased overall mortality in patients 70 years of age and in
patients with a BMI30 kg/m2, but not older or obese patients.Moderate and severe
PPM were both associated with increased mortality in patients with left ventricular
(LV) ejection fraction 50%. PPM is associated with increased late mortality in
patients with LV dysfunction, in patients70 years of age, and in those with a BMI
30 kg/m2. See page 39. See figure.(continued on page A-26)
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Peripheral Vascular Disease
Cilostazol Improves Outcomes After Lower Extremity Angioplasty
Soga and colleagues performed a multicenter, randomized, open-label clinical trialof cilostazol in patients who underwent angioplasty with provisional stenting for a
femoropopliteal lesion. Freedom from target vessel revascularization (TVR) andbinary
restenosis were both significantly lower in those randomized to cilostazol. There were
no major bleeding complications. Cilostazol reduces restenosis and TVR after angio-
plasty for femoropopliteal disease. See page 48. See figure.
Year in Cardiology Series
Year in Cardiac Imaging—2008
This review by Gibbons and colleagues covers the 15-month period from April2007 to June 2008 highlighting what the authors feel are the most important
publications related to cardiac imaging. It is organized into topical themes reflecting the
growing interest in integratedmultimodality imaging. A brief synopsis of key studies is
provided with the goal of encouraging the reader to examine at least some of these
articles in more detail. See page 54.
